In November 2004, a national target was set for hospitals in England to reduce the methicillin-resistant Staphylococcus aureus (MRSA) bactermia rate by 60 percent by April 2008 against the number during 2003/04 (baseline year). Sarma, et al. (2013) report that in their organization the number of MRSA bactermias has risen since 2002 and peaked at 75 in 2005/06. A target was set to reduce the number and string of specific and non-specific interventions was introduced including universal MRSA screening. This study analyzes the impact of universal MRSA screening using a quasi-experimental design using routinely gathered data.
Â
This study used data gathered routinely for clinical governance, quality control, financial management and outbreak monitoring purposes. Interrupted Time Series (ITS) analysis of 15 pre- and 19 post- universal MRSA screening (and decolonization) quarterly numbers of bactermias was carried out where methicillin-sensitive Staphylococcus aureus (MSSA) numbers served as non-equivalent dependent variable (control).
Â
An immediate sharp decrease in MRSA bactermias was observed following the universal MRSA screening (and decolonization) commenced in Q2, 2007. The number dropped sharply from 23 (Q2, 2007) to 10 (Q3, 2007) all MRSA bactermias, and, from 15 (Q2, 2007) to 6 (Q3, 2007) for bactermias >= 48 hours of hospitalization. The declining trend continued reaching zero in Q2, 2009 and Q4, 2010 for those with >=48 hours of hospitalization and, all bactermias, respectively. ITS analysis revealed significant impact of universal MRSA screening on all MRSA bactermias (beta2 -0.554, p 0.000) and those with >=48 of hospitalization (beta2 -0.577, p 0.001), respectively. Impact estimation predicted 17 and 13 bactermias for all and those with >=48 hours hospitalization, respectively in the 19th quarter post-intervention, if the intervention did not occur. The number of MRSA isolates from non-blood culture systemic sources as percentage of admissions also dropped significantly from 3.32 percent in Q2, 2007 to 1.51 percent in Q3, 2007 (beta2 -0.506, p 0.000) which is still running low at 0.33 percent at the end of Q1, 2012. On the other hand, there was no statistically significant impact of universal screening on MSSA bactermias.
Â
The researchers conclude that of all interventions, the universal MRSA screening (and decolonization) is the most effective intervention associated with significant and sharp drop in MRSA burden. Their research was published in Antimicrobial Resistance and Infection Control.Â
Reference: Sarma JB, Marshall B, Cleeve V, Tate D and Oswald T. Impact of universal screening on MRSA bactermias in a single acute NHS organisation (2006--12): interrupted time-series analysis Antimicrobial Resistance and Infection Control 2013, 2:2 doi:10.1186/2047-2994-2-2
Â
Implementing FDA 21 CFR Part 820 & ISO 13485 on Quality System Regulation
August 30th 2024The FDA's 21 CFR Part 820 and ISO 13485 are crucial in regulating medical device quality systems. Harmonizing these standards by 2026 will streamline compliance, improve patient access to devices, and align US regulations with global practices.
The Long-Term Care Chronicles: The Great Mitigators
August 27th 2024Enjoy this first installment of The Long-Term Care Chronicles With Robbie Hilliard, MSN, RN CIC, a column about managing special infection control situations in the long-term care patient population. This installment is about when 2 experts conflict about best care.
Urgent Need for a Paradigm Shift in Infectious Disease Control Amid 2024 Outbreaks
August 26th 2024The 2024 surge in infectious diseases like mpox, measles, and meningitis demands a paradigm shift in control strategies, emphasizing expanded expertise, improved airborne precautions, and rethinking cost-effectiveness in healthcare to prevent future outbreaks and protect public health.
Navigating Infection Prevention Challenges Amid 2024 Outbreaks: Strategies for Success
August 22nd 2024As infectious diseases resurge in 2024, this article explores how IPs can manage outbreaks, allocate resources, use technology for surveillance, and collaborate with senior leaders to ensure business continuity and patient safety in health care settings.